1. Medtech Insight
  2. >>Business

Market Brief: Blood Gas Monitoring Systems Market Expected To Reach $4.9Bn By 2023

 
• By Marion Webb

The global market for blood gas monitoring systems is expected to grow 6.1% annually to reach $4.9bn in 2023, driven by the rising prevalence of chronic diseases, the aging population, and pressure on medical device makers to introduce smart devices that improve outcomes while reducing cost of care.

Blood haematology analyzer. Close up of medical worker in lab. - Image

The global market for blood gas monitoring products is expected to grow from $3.6bn in 2018 to $4.9bn in 2023, for a compound annual growth rate of 6.1%, according to "Blood Gas Monitoring Systems," a new analysis from Informa's Meddevicetracker.

The top three top competitors in the blood gas monitoring systems market are Medtronic Minimally Invasive Therapies, Masimo Corp. and Abbott Laboratories Inc., accounting for 58% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.